NCT07196033Recruiting
Asian Gynecological Brachytherapy Registry in Cervical Cancer
Source: ClinicalTrials.gov · Last updated 9 Feb 2026
Brief summary (registry, in English)
Gynecological cancer poses as significant public health issue, especially in Asian countries, where it is a leading cause of cancer-related deaths among women. Cervical cancer accounts for around 311,000 deaths annually, with over 85% occurring in low- and middle-income nations, primarily in Asia. Factors contributing to this burden include limited access to preventive care, inadequate screening, high rates of human papillomavirus infection, and cultural barriers that delay medical attention. For patients with advanced cervical cancer, the standard treatment involves external beam radiation therapy along with chemotherapy followed by internal radiation, known as Brachytherapy. This technique uses unique set of devices placed internally at the tumor sitegiving localized radiation to the residual tumor tissue. While advanced brachytherapy techniques have been developed and practiced in Europe and American countries yielding excellent clinical outcomes, there is insufficient data on the use and results of such advanced brachytherapy techniques in Asian populations, leading to a lack of standardized practices. To address these issues, the Asian Gynecological Brachytherapy Registry (ABGR) has been established as a collaborative platform for data collection and analysis on the use of Brachytherapy techniques. This registry aims to consolidate information from various healthcare settings across Asia, enhancing understanding of cervical cancer's epidemiology, evaluating treatment effectiveness, and identifying areas for improvement in patient care.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 19 Sept 2025
- Start date
- Feb 2026
- Primary completion date
- Mar 2028
- Lead sponsor
- Tata Memorial Hospital
- Diseases
- Cervical cancer, Childhood cancers
- NCT number
- NCT07196033
What you commit to
- Study type: Observational
- Planned participants: 1000
- From Feb 2026 to the primary completion date, Mar 2028
- 5 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Neuroendocrine cancer of the cervix or other rare histology subtypes.
- Patients with metastatic cervix cancer and not planned for radical doses of pelvic RT/brachytherapy may be excluded.
- Patients undergoing postoperative RT or RT for recurrent disease should be excluded.
Who the study is looking for
- Patients diagnosed with FIGO 2018 stage IB-IVA cervical cancer with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma histological subtype.
- Planned for treatment with definitive chemo-radiation and brachytherapy. (X- ray,CT, CT-Ultrasound or MRI based).
Sex: Female · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tata Memorial Center Coordinator of this site? Confirm its status | Mumbai | India | Recruiting |
| Gunma University Coordinator of this site? Confirm its status | Maebashi | Japan | Not yet recruiting |
| Juntendo University Coordinator of this site? Confirm its status | Tokyo | Japan | Not yet recruiting |
| Mahidol University Coordinator of this site? Confirm its status | Bangkok | Thailand | Not yet recruiting |
| Chiang Mai University Coordinator of this site? Confirm its status | Chiang Mai | Thailand | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.